Ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. Ocuphire’s lead drug candidate, Nyxol eye drops, is aimed to treat patients with night vision disturbances (NVD), Glaucoma and Presbyopia (impaired near-term vision).

Ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. Ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.